Asthalin Respirator Solution
Prescription required
Highlights
description
A bronchodilator medication used in a nebulizer for the treatment and prevention of bronchospasm in conditions like asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles in the airways, making breathing easier. This unit-dose respule is administered via a nebulizer machine. Common side effects include tremors, headache, and a fast heartbeat.
how to use
Twist off the top of the respule/transpule and squeeze all the liquid into the nebulizer. It should be used right away after opening.
side effects
Tremors, Headache, Fast heartbeat, Palpitations
Information
disclaimer
The contents and images displayed on this Platform are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a registered medical practitioner with any questions you may have regarding a medical condition or the use of any product. Do not disregard professional medical advice or delay seeking it because of something you have read on this Platform.We intend to support, not replace, the doctor-patient relationship.
While we make every effort to ensure the information provided is accurate and up-to-date, we strongly recommend reviewing product labels, batch numbers, manufacturing and packaging details, as well as any warnings and usage instructions before using or consuming any product.
customer care details
In case of any issue, contact us
E-mail address: support@zeptonow.com
Seller Name
Drogheria Sellers Private Limited
Seller Address
Brigade IRV, 9th & 10th Floors, Nallurhalli, White Field, Bangalore, Banglore, Karnataka, India, 560066 For Support ReachOut : support+drogheria@zeptonow.com
Pharmacy License No.
MH-TZ1-581061, MH-TZ1-581062
Manufacturer or Marketer Name
Cipla Limited
Manufacturer or Marketer Address
Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel Mumbai 400013
Country of Origin
India
Shelf Life
24 months
Expires on or after
December 2026
